Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials. J of Skin [Internet]. 2022 Nov. 16 [cited 2025 Apr. 19];6(6):s71. Available from: https://skin.dermsquared.com/skin/article/view/1827